Category Archives: Global
By Pharm Exec | Published: September 25, 2014
The Non-Hodgkin Lymphoma (NHL) treatment market in the Asia-Pacific (APAC) countries of India, Australia, China and Japan will expand from $1.1 billion in 2013 to $1.7 billion by 2020, with Japan remaining the largest contributor to growth, according to GBI Research. The company’s new report says that Japan had a 67.2% share of the APAC […]
By Guest Blogger | Published: September 24, 2014
What can be gleaned about the direction that health policy will take for the next five years under the new European Commission, scheduled to take office at the beginning of November? Peter O’ Donnell address this question in his new Applied Clinical Trials column here.
By Jill Wechsler | Published: September 24, 2014
Although biopharmaceutical companies and regulatory authorities have made considerable progress in establishing policies for bringing biosimilars to market, key differences and gaps in requirements for testing and documenting product similarity still characterize the European Union, the U.S. and other regions. The EU’s European Medicines Agency (EMA) has set the regulatory pace, with 18 products approved since 2006, […]
By Pharm Exec | Published: September 18, 2014
By Casey McDonald. GSK will weigh in on non-communicable diseases (NCDs) in Africa with a £1m contribution and a commitment of internal R&D expertise supporting researchers from South African institutions, the company announced this month.
By Guest Blogger | Published: September 17, 2014
Biopharmaceutical manufacturing is following the general pharmaceutical market trend toward global expansion. BioPlan Associates’ 11th Annual Report and Survey of Biopharmaceutical Manufacturing Capacity and Production identifies the markets best poised to profit from the internationalization of the outsourcing, finding that emerging markets such as China and India are among top potential destinations for both US and Western […]